{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:59:54Z","timestamp":1781359194186,"version":"3.54.1"},"reference-count":47,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Xenobiotica"],"published-print":{"date-parts":[[2023,5,4]]},"DOI":"10.1080\/00498254.2023.2250856","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:37:41Z","timestamp":1692783461000},"page":"366-381","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Physiologically based pharmacokinetic modelling to predict drug\u2013drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors"],"prefix":"10.1080","volume":"53","author":[{"given":"Sivacharan","family":"Kollipara","sequence":"first","affiliation":[{"name":"KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tausif","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Biopharmaceutics Group, Global Clinical Management, Dr. Reddy\u2019s Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivadasu","family":"Praveen","sequence":"additional","affiliation":[{"name":"KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.708299"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.02.002"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04179-w"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtcomm.2022.103757"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1769"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14609"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-023-00463-1"},{"key":"e_1_3_3_9_1","unstructured":"Del Frari L Lukacova V Reddy M. 2023. Real world impact\u00a0+\u00a0regulatory decision making track poster presentation: building of encorafenib physiologically based pharmacokinetic model and its qualification to predict drug drug interaction with posaconazole. In: MIDD 2023 Conference Simulations-Plus; [accessed 2023 Jun 15]. https:\/\/www.simulations-plus.com\/wp-content\/uploads\/Laurence_DelFrari-MIDD_16FEB2023.pdf."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.10.032"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"e_1_3_3_12_1","unstructured":"EMA. 2013. Guideline on the investigation of drug interactions; [accessed 2023 Jun 15]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf."},{"key":"e_1_3_3_13_1","unstructured":"EMA. 2018a. Encorafenib summary of product characteristics; [accessed 2023 Jun 15]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/braftovi-epar-product-information_en.pdf."},{"key":"e_1_3_3_14_1","unstructured":"EMA. 2018b. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation; [accessed 2023 Jun 15]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf."},{"key":"e_1_3_3_15_1","unstructured":"EMA. 2018c. Encorafenib public assessment report; [accessed 2023 Aug 16]. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/braftovi-epar-public-assessment-report_en.pdf."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1018918917046"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1741"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12870"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.036103"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000426"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2023.2246153"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02521-y"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.562"},{"key":"e_1_3_3_24_1","unstructured":"Lukacova V Parrott NJ Lave T Franczkiewicz G Bolger MB Woltosz WS. 2008. General approach to calculation of tissue: plasma partition coefficients for physiologically based pharmacokinetic (PBPK) modeling; [accessed 2023 Jun 15]. https:\/\/www.simulations-plus.com\/wp-content\/uploads\/Lukacova-General_Approach_Calc_Tissue_Plasma_Partition_Coefficients_PBPK_Modeling-AAPS-2008-1.pdf."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9451-0"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061586"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.035"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00040"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00016"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22619"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10868"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00659-w"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20502"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100795"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-106289"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1570847"},{"key":"e_1_3_3_37_1","unstructured":"USFDA. 2018a. Encorafenib multi-disciplinary review; [accessed 2023 Jun 15]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210496Orig1s000MultidisciplineR.pdf."},{"key":"e_1_3_3_38_1","unstructured":"USFDA. 2018b. Encorafenib label; [accessed 2023 Jun 15]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210496s006lbl.pdf."},{"key":"e_1_3_3_39_1","unstructured":"USFDA. 2020. Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions; [accessed 2023 Jun 15]. https:\/\/www.fda.gov\/media\/134581\/download."},{"key":"e_1_3_3_40_1","unstructured":"USFDA. 2020a. The use of physiologically based pharmacokinetic analyses-biopharmaceutics applications for oral drug product development manufacturing changes and controls guidance for industry; [accessed 2023 Jun 15]. https:\/\/www.fda.gov\/media\/142500\/download."},{"key":"e_1_3_3_41_1","unstructured":"USFDA. 2020b. Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions; [accessed 2023 Jun 15]. https:\/\/www.fda.gov\/media\/134581\/download."},{"key":"e_1_3_3_42_1","unstructured":"USFDA. 2023. Drug development and drug interactions | table of substrates inhibitors and inducers; [accessed 2023 Jun 15]. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0795"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03319-6"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12915"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2011.04.008"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.013847"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.04.004"}],"container-title":["Xenobiotica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00498254.2023.2250856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T10:08:07Z","timestamp":1696500487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00498254.2023.2250856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,4]]}},"alternative-id":["10.1080\/00498254.2023.2250856"],"URL":"https:\/\/doi.org\/10.1080\/00498254.2023.2250856","relation":{},"ISSN":["0049-8254","1366-5928"],"issn-type":[{"value":"0049-8254","type":"print"},{"value":"1366-5928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}